Pimavanserin: A Novel Drug Approved to Treat Parkinson’s Disease Psychosis

| February 1, 2018 | 0 Comments

by Amanda K. Kitten, PharmD; Sarah A. Hallowell, PharmD; Stephen Saklad, PharmD, BCPP; and Kirk E. Evoy, PharmD, BCACP, BC-ADM, CTTS
Drs. Kitten, Hallowell, Saklad, and Evoy are with the College of Pharmacy, The University of Texas at Austin in Austin, Texas.

Innov Clin Neurosci. 2017;15(1–2):16–22


The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , ,

Category: Movement Disorders, Neurology, Parkinson's disease, Past Articles, Psychiatry, Psychopharmacology, psychosis, Review, Schizophrenia

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.